News Breaks |
|
|
| September 30, 2012 |
| 15:18 EDT |  | LLY | Lilly releases Phase II results for monoclonal antibody ramucirumab
Eli Lilly announced new data from two Phase II ramucirumab (IMC-1121B) trials in patients with non-small cell lung cancer, NSCLC. Results were presented during the Lung Cancer – Metastatic Poster Session at the ESMO 2012 Congress (European Society for Medical Oncology). Interim data for a study in chemotherapy-naive patients with advanced NSCLC treated with ramucirumab in combination with first-line ALIMTA (pemetrexed for injection)/platinum-based chemotherapy and final data for a study in patients treated with ramucirumab in combination with paclitaxel/carboplatinum chemotherapy were presented. The pre-specified interim analysis of progression-free survival and final six-month PFS rate support continued development of ramucirumab in lung cancer. "We are encouraged by these results from two Phase II trials indicating ramucirumab may be beneficial to patients with non-small cell lung cancer," said Richard Gaynor, M.D., vice president, product development and medical affairs for Lilly Oncology. "These findings support our ongoing evaluation of ramucirumab for lung cancer patients and will need to be confirmed in larger pivotal studies." |
|
|
News For LLY From The Last 14 Days Check below for free stories on LLY the last two weeks. |
|
|
| June 19, 2013 |
| 15:17 EDT | | LLY | Eli Lilly issues alert for illegal scams
Eli Lilly and Company issued an alert about two illegal scams, purportedly using the name of the company and/or its subsidiary Elanco Animal Health, that are actively targeting the public through postal mail solicitations and job-seekers through online dialogue. Lilly and Elanco have no connection to any foreign lottery organizations and do not conduct the type of online recruiting described by the job-seeking victims of the scam. The activities described in these scams are completely fraudulent and are in no way affiliated with, or sponsored by, Eli Lilly and Company or its affiliates or subsidiaries. |
|
| June 18, 2013 |
| 10:17 EDT |  | LLY | Lilly puts active on FDA says investigating two deaths after Zyprexa injections
 Subscribe for More Information |
|
| 10:12 EDT | | LLY | FDA investigating two deaths of patients taking Lilly's Zyprexa
The FDA said in a safety announcement on its website that it is investigating two unexplained deaths in patients who received an intramuscular injection of the antipsychotic drug Zyprexa. The patients died 3-4 days after receiving an appropriate dose of the drug, well after the 3-hour post-injection monitoring period required under the Zyprexa Risk Evaluation and Mitigation Strategy, the agency said. Both patients were found to have very high olanzapine blood levels after death. Eli Lilly is the maker of Zyprexa. |
|
| June 17, 2013 |
| 11:34 EDT | | LLY | Eli Lilly: LIVALO 4mg has neutral effects on fasting serum glucose levels
Kowa Pharmaceuticals America and Eli Lilly and Company announced results of a pre-specified safety analysis from the INTREPID (HIV-infected patieNts and TREatment with PItavastatin vs. pravastatin for Dyslipidemia) trial evaluating the effect of LIVALO 4 mg compared with pravastatin 40 mg on changes in levels of blood glucose and glycated hemoglobin in HIV-infected adults with dyslipidemia. INTREPID was a Phase 4, multicenter, 12-week randomized superiority study followed by a 40-week safety extension study comparing the lipid-lowering effects of pitavastatin 4 mg and pravastatin 40 mg in adults with HIV infection and dyslipidemia. The results of this pre-specified safety analysis, presented yesterday at the Endocrine Society's 95th Annual Meeting & Expo in San Francisco, CA, showed neutral effects of pitavastatin 4 mg and pravastatin 40 mg on fasting serum glucose and HbA1c levels over 12 weeks. |
|
| 11:17 EDT |  | LLY | Eli Lilly to host conference call
Subscribe for More Information |
|
| 06:06 EDT | | LLY | Transition Therapeutics announces exercise of TT-401 rights by Eli Lilly
Transition Therapeutics (TTHI) announced that Eli Lilly (LLY) has exercised its option to assume all development and commercialization rights to type 2 diabetes drug candidate TT-401. In conjunction with this assumption of rights, Transition will receive a $7M milestone payment. Lilly and Transition have amended their agreement to address future development of TT-401 and associated financial arrangements. Lilly will assume all costs and perform all future development and commercialization activities of TT-401. Transition will contribute payment of $14M to Lilly in three separate installments during the Phase 2 clinical study. If TT-401 is successfully commercialized, Transition will be eligible to receive approximately $240M in additional milestone payments. Transition will also be eligible to receive a double-digit royalty on sales of TT-401 products and a low single digit royalty on related compounds. |
|
| June 13, 2013 |
| 16:45 EDT | | LLY | Eli Lilly terminates Phase II study for beta secretase inhibitor
Subscribe for More Information |
|
| 14:36 EDT | | LLY | Lilly, Boehringer Ingelheim support ADA call for review of incretin therapies
Subscribe for More Information |
|
| 14:33 EDT | | LLY | Eli Lilly July volatility elevated into diabetes business update
Subscribe for More Information |
|
| 06:05 EDT | | LLY | Eli Lilly, Incyte announce efficacy data of baricitinib Phase 2b JADA study
Subscribe for More Information |
| |
|
|
|
|
